Volition to participate in a lung cancer screening study in france

Henderson, nev. , nov. 10, 2022 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has been invited to participate in a government-backed prospective study to evaluate the performance of blood biomarkers in the early detection of lung cancer with hospices civils de lyon ("hcl"), france's second largest university hospital.

VNRX Ratings Summary

VNRX Quant Ranking